Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280492745> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W4280492745 endingPage "520" @default.
- W4280492745 startingPage "520" @default.
- W4280492745 abstract "HaemophiliaVolume 28, Issue 3 p. 520-520 CORRIGENDUMFree Access This article corrects the following: Health technology assessment for gene therapies in haemophilia Jamie O'Hara, Peter J. Neumann, , Volume 28Issue S2Haemophilia pages: 19-26 First Published online: January 25, 2022 First published: 10 May 2022 https://doi.org/10.1111/hae.14580AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In Table 1 of the article by O'Hara and Neumann,1 the first row of the ‘Haemophilia B gene therapy trials’ was missing in the published version. TABLE 1. Summary of gene therapies trials enrolling ≥10 persons with haemophilia A and B Intervention Sponsor NCT Number Phase N (planned) Status Haemophilia A gene therapy trials Valoctocogene Roxaparvovec (BMN 270) BioMarin NCT03370913 3 134 Active NCT03392974 3 40 Active NCT03520712 1/2 10 Recruiting PF-07055480 (giroctocogene fitelparovec) Pfizer NCT04370054 3 63 Active BAY2599023 (DTX201), AAVhu37FVIII Bayer NCT03588299 1/2 30 Recruiting SB-525, AAV6-co-BDD-F8 Pfizer NCT03061201 2 11 Active BAX 888, AAV8-co-BDD-F8 Baxalta/Shire NCT03370172 1/2 12 Active BMN270, AAV5-co-BDD-F8 BioMarin NCT02576795 1/2 15 Active SPK-8011, LK03-co-BDD-F8 Spark NCT03003533 1/2 30 Recruiting NCT03432520 - 100 Enrolling AAV2/8-HLP-FVIII-V3 University College, London/Medical Research Council NCT03001830 1 18 Recruiting YUVA-GT-F801- Lentiviral vector F8HSC Shenzhen Geno-Immune Medical Institute NCT03217032 1 10 Not yet recruiting Haemophilia B gene therapy trials Etranacogene dezaparvovec (CSL222, formerly AMT-061) CSL Behring / UniQure NCT03569891 3 54 Completed, long-term follow up PF-06838435 (fidanacogene elaparvovec) Pfizer NCT03861273 3 55 Active SPK-9001, mutant AAV8-coF9-Padua Spark/Pfizer NCT02484092 2 15 Completed NCT03307980 2 20 Recruiting AskBio009, AAV8-coF9-Padua Baxalta/Shire NCT01687608 1/2 30 Active AAV5-hFIX (AMT-060) UniQure Biopharma NCT02396342 1/2 10 Completed SB-FIX, AAV6-zinc-finger nuclease Alb locus and AAV6-F9donor template Sangamo NCT02695160 1 12 Terminated scAAV2/8-LP1-hFIXco St. Jude Children's Research Hospital/ National Heart, Lung, and Blood Institute/ Haemophilia of Georgia, Inc./ Children's Hospital of Philadelphia NCT00979238 1 14 Active FLT180a University College, London NCT03369444 1 24 Terminated The correct table is presented below. The online version of the article has been corrected. REFERENCE 1O'Hara J, Neumann PJ. Health technology assessment for gene therapies in haemophilia. Haemophilia. 2022; 28(Suppl. 2): 19– 26. https://doi.org/10.1111/hae.14413 Volume28, Issue3May 2022Pages 520-520 ReferencesRelatedInformation" @default.
- W4280492745 created "2022-05-22" @default.
- W4280492745 date "2022-05-01" @default.
- W4280492745 modified "2023-10-16" @default.
- W4280492745 title " " @default.
- W4280492745 cites W4207034731 @default.
- W4280492745 doi "https://doi.org/10.1111/hae.14580" @default.
- W4280492745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35536736" @default.
- W4280492745 hasPublicationYear "2022" @default.
- W4280492745 type Work @default.
- W4280492745 citedByCount "0" @default.
- W4280492745 crossrefType "journal-article" @default.
- W4280492745 hasConcept C138885662 @default.
- W4280492745 hasConcept C187212893 @default.
- W4280492745 hasConcept C2776863037 @default.
- W4280492745 hasConcept C2777081929 @default.
- W4280492745 hasConcept C2777232031 @default.
- W4280492745 hasConcept C2778385053 @default.
- W4280492745 hasConcept C41895202 @default.
- W4280492745 hasConcept C512399662 @default.
- W4280492745 hasConcept C71924100 @default.
- W4280492745 hasConceptScore W4280492745C138885662 @default.
- W4280492745 hasConceptScore W4280492745C187212893 @default.
- W4280492745 hasConceptScore W4280492745C2776863037 @default.
- W4280492745 hasConceptScore W4280492745C2777081929 @default.
- W4280492745 hasConceptScore W4280492745C2777232031 @default.
- W4280492745 hasConceptScore W4280492745C2778385053 @default.
- W4280492745 hasConceptScore W4280492745C41895202 @default.
- W4280492745 hasConceptScore W4280492745C512399662 @default.
- W4280492745 hasConceptScore W4280492745C71924100 @default.
- W4280492745 hasIssue "3" @default.
- W4280492745 hasLocation W42804927451 @default.
- W4280492745 hasLocation W42804927452 @default.
- W4280492745 hasOpenAccess W4280492745 @default.
- W4280492745 hasPrimaryLocation W42804927451 @default.
- W4280492745 hasRelatedWork W2005719195 @default.
- W4280492745 hasRelatedWork W2031327112 @default.
- W4280492745 hasRelatedWork W2067082011 @default.
- W4280492745 hasRelatedWork W2076774328 @default.
- W4280492745 hasRelatedWork W2078332762 @default.
- W4280492745 hasRelatedWork W2101928171 @default.
- W4280492745 hasRelatedWork W2121648797 @default.
- W4280492745 hasRelatedWork W2164704082 @default.
- W4280492745 hasRelatedWork W2414324994 @default.
- W4280492745 hasRelatedWork W4292525692 @default.
- W4280492745 hasVolume "28" @default.
- W4280492745 isParatext "false" @default.
- W4280492745 isRetracted "false" @default.
- W4280492745 workType "article" @default.